Treatment of Kearns-Sayre syndrome with coenzyme Q10.
We studied the metabolism of coenzyme Q10 (CoQ) and the effects of CoQ therapy in five patients with Kearns-Sayre syndrome (KSS). Although the mitochondrial fraction was increased in muscles from KSS patients, CoQ content was slightly low. CoQ synthesis was normal in fibroblasts from KSS patients. Administration of 120 to 150 mg/d of CoQ improved abnormal metabolism of pyruvate and NADH oxidation in skeletal muscle. CoQ therapy decreased CSF protein concentration and CSF lactate/pyruvate ratio. ECG abnormalities and neurologic symptoms also improved.
D000328:Adult; D002037:Bundle-Branch Block / Q000150:complications / Q000188:drug therapy / Q000503:physiopathology; D003067:Coenzymes; D004562:Electrocardiography; D004579:Electron Transport; D005073:Evoked Potentials, Somatosensory; D005080:Exercise Test; D005260:Female; D006801:Humans; D007625:Kearns-Sayre Syndrome / Q000150:complications / Q000188:drug therapy* / Q000503:physiopathology; D007773:Lactates / Q000378:metabolism; D008297:Male; D008475:Median Nerve / Q000503:physiopathology; D008931:Mitochondria, Muscle / Q000378:metabolism; D009886:Ophthalmoplegia / Q000188:drug therapy*; D011773:Pyruvates / Q000378:metabolism; D011930:Reaction Time; D014451:Ubiquinone / Q000031:analogs & derivatives* / Q000378:metabolism / Q000627:therapeutic use
D003067:Coenzymes; D007773:Lactates; D011773:Pyruvates; D014451:Ubiquinone; C024989:coenzyme Q10